
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Revelation Biosciences Inc (REVB)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: REVB (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $60
1 Year Target Price $60
0 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.22% | Avg. Invested days 8 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.39M USD | Price to earnings Ratio - | 1Y Target Price 60 |
Price to earnings Ratio - | 1Y Target Price 60 | ||
Volume (30-day avg) 1 | Beta -0.05 | 52 Weeks Range 2.11 - 100.32 | Updated Date 08/15/2025 |
52 Weeks Range 2.11 - 100.32 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 866.22 |
Earnings Date
Report Date 2025-08-08 | When - | Estimate -9 | Actual -7.01 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -57.37% | Return on Equity (TTM) -340.81% |
Valuation
Trailing PE - | Forward PE 0.89 | Enterprise Value -788808 | Price to Sales(TTM) 2.88 |
Enterprise Value -788808 | Price to Sales(TTM) 2.88 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.02 | Shares Outstanding 1699640 | Shares Floating 1684289 |
Shares Outstanding 1699640 | Shares Floating 1684289 | ||
Percent Insiders 0.9 | Percent Institutions 0.81 |
Upturn AI SWOT
Revelation Biosciences Inc
Company Overview
History and Background
Revelation Biosciences Inc. is a clinical-stage biopharmaceutical company focused on the development of immunomodulatory therapies for the prevention and treatment of disease. Founded in 2011, they have evolved from initially focusing on respiratory diseases to a broader range of inflammatory and infectious diseases. They are using their REVTx-99 platform.
Core Business Areas
- REVTx-99: Intranasal immunomodulator being developed for prevention of respiratory viral infections.
- REVTx-300: Being developed as a potential therapy for chronic organ inflammation, and has the potential to improve clinical outcomes in inflammatory bowel disease.
- REVBx-100: A diagnostic aid for detection of potential tissue damage secondary to ischemic events. A biomarker panel for early diagnosis of acute kidney injury (AKI) during surgical procedures.
Leadership and Structure
James Rolke is the CEO. The company operates with a typical biotech organizational structure, with departments focused on research and development, clinical trials, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- REVTx-99: An intranasal spray being developed for preventing respiratory viral infections, including influenza and SARS-CoV-2. Currently in clinical trials. Market share is currently 0 as it is not yet approved. Competitors include companies developing vaccines and antiviral therapies for respiratory viruses, such as Pfizer (Paxlovid), Moderna (mRNA vaccines) and Gilead (Tamiflu).
- REVTx-300: An investigational product for the treatment of inflammatory bowel disease. Market share is currently 0 as it is not yet approved. Competitors include companies that make anti-inflammatory drugs such as Takeda(Entyvio), Abbvie(Humira), and Janssen Biotech (Stelara).
- REVBx-100: A diagnostic aid for early detection of Acute Kidney Injury in hospitals. Market share is currently 0 as it is not yet approved. Key competitors are bioMu00e9rieux (Astute Medical) and Beckman Coulter(Dx).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Recent trends include increased focus on personalized medicine, gene therapy, and immunomodulatory therapies.
Positioning
Revelation Biosciences is a clinical-stage company aiming to establish itself in the immunomodulatory therapeutics market. Competitive advantages will depend on clinical trial success and regulatory approvals.
Total Addressable Market (TAM)
The TAM for respiratory viral infection preventatives and inflammatory bowel disease treatments are each multi-billion dollar markets. REV is currently in a developing stage and is positioned to capture a portion of these markets if trials are successful.
Upturn SWOT Analysis
Strengths
- Novel immunomodulatory technology platform
- Experienced management team
- Diverse pipeline of product candidates
Weaknesses
- Clinical stage company with no approved products and no revenue
- Dependence on successful clinical trial outcomes
- High cash burn rate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisitions or licensing
- Advancements in regulatory pathways for immunomodulatory therapies
Threats
- Failure to obtain regulatory approvals
- Competition from established pharmaceutical companies
- Unfavorable clinical trial results
- Limited funding
Competitors and Market Share
Key Competitors
- MRNA
- PFE
- ABBV
- TAK
- JNJ
- GILD
Competitive Landscape
Revelation Biosciences faces strong competition from established pharmaceutical companies with greater resources and approved products. Its success hinges on demonstrating superior efficacy and safety of its product candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increased R&D spending and clinical trial activity.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals for REVTx-99 and REVTx-300. Analyst estimates are speculative and highly dependent on these factors.
Recent Initiatives: Recent initiatives include advancing REVTx-99 into Phase 2 clinical trials and exploring partnerships for further development of the pipeline.
Summary
Revelation Biosciences is a high-risk, high-reward clinical-stage biopharmaceutical company. Its novel immunomodulatory technology holds promise, but success is contingent on positive clinical trial results and regulatory approvals. Financial stability is a key concern, requiring continuous funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and is subject to change. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Revelation Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-11-17 | Chairman & CEO Mr. James M. Rolke | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.revbiosciences.com |
Full time employees 8 | Website https://www.revbiosciences.com |
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.